Thanks tada and bear for your insights. Tada my sense is that if Zenith cannot make the picture clear and obvious then the findings are not obvious and clear.

I noted on page 10 of the Bio Europe deck the point near the arrow tip saying "POC, molecular characterization, patient stratification strategy". It seems to me that if this process leads to understanding why the 3 super star patients results are different from others on zen3694 then this may lead to a targetting strategy for zen3694. In essence if the 3 patients represent a significant mCRPC segment that can be pre isolated and if the size of this population can be determined then there may be a patient market to apply zen3694 to.

This, in turn could lead to clarity of why/how the drug works. Any thoughts? Am i off base?

Toinv